Haixi Pharma Shares Surge Over 14% on US FDA Approval for Phase 2 Clinical Trial of HX9428

Deep News08-05 10:30

HAIXI PHARMA (02637) shares jumped more than 14% in early trading, before settling to a gain of 5.42% at HK$196.40, with a trading volume of HK$21.28 million.

The company announced that its self-developed innovative drug candidate, HX9428, for the treatment of neovascular age-related macular degeneration (nAMD), has received approval from the US Food and Drug Administration (FDA) to commence a Phase 2 clinical trial in the United States. Simultaneously, Haixi Pharma has initiated a second Phase 2 trial in China, using a positive control (Aflibercept), planning to enroll 60 patients.

Public information indicates that HX9428 is an oral innovative drug candidate designed to overcome the current reliance on intravitreal injections for nAMD treatment, offering a more convenient dosing regimen to improve long-term patient compliance. Prior studies have completed Phase 1 and Phase 2 dose expansion stages.

The company stated that the US Phase 2 approval and the initiation of the controlled study in China represent significant progress in global clinical development. HX9428 has not yet been approved for marketing, and its safety and efficacy require further validation.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1158428386?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 10:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158428386","market":"sg","top_or_hot":-1,"title":"Haixi Pharma Shares Surge Over 14% on US FDA Approval for Phase 2 Clinical Trial of HX9428","media":"Deep News","content":"<p><b>HAIXI PHARMA (02637)</b> shares jumped more than 14% in early trading, before settling to a gain of 5.42% at HK$196.40, with a trading volume of HK$21.28 million.<br><br>The company announced that its self-developed innovative drug candidate, HX9428, for the treatment of neovascular age-related macular degeneration (nAMD), has received approval from the US Food and Drug Administration (FDA) to commence a Phase 2 clinical trial in the United States. Simultaneously, <b>Haixi Pharma</b> has initiated a second Phase 2 trial in China, using a positive control (Aflibercept), planning to enroll 60 patients.<br><br>Public information indicates that HX9428 is an oral innovative drug candidate designed to overcome the current reliance on intravitreal injections for nAMD treatment, offering a more convenient dosing regimen to improve long-term patient compliance. Prior studies have completed Phase 1 and Phase 2 dose expansion stages.<br><br>The company stated that the US Phase 2 approval and the initiation of the controlled study in China represent significant progress in global clinical development. HX9428 has not yet been approved for marketing, and its safety and efficacy require further validation.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Haixi Pharma Shares Surge Over 14% on US FDA Approval for Phase 2 Clinical Trial of HX9428</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHaixi Pharma Shares Surge Over 14% on US FDA Approval for Phase 2 Clinical Trial of HX9428\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-08-05 10:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>HAIXI PHARMA (02637)</b> shares jumped more than 14% in early trading, before settling to a gain of 5.42% at HK$196.40, with a trading volume of HK$21.28 million.<br><br>The company announced that its self-developed innovative drug candidate, HX9428, for the treatment of neovascular age-related macular degeneration (nAMD), has received approval from the US Food and Drug Administration (FDA) to commence a Phase 2 clinical trial in the United States. Simultaneously, <b>Haixi Pharma</b> has initiated a second Phase 2 trial in China, using a positive control (Aflibercept), planning to enroll 60 patients.<br><br>Public information indicates that HX9428 is an oral innovative drug candidate designed to overcome the current reliance on intravitreal injections for nAMD treatment, offering a more convenient dosing regimen to improve long-term patient compliance. Prior studies have completed Phase 1 and Phase 2 dose expansion stages.<br><br>The company stated that the US Phase 2 approval and the initiation of the controlled study in China represent significant progress in global clinical development. HX9428 has not yet been approved for marketing, and its safety and efficacy require further validation.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02637","symbol_name":"海西新药","start_time":0,"source_url":"","article_id":"1158428386","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158428386","pubTimestamp":1785897057,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"HAIXI PHARMA (02637) shares jumped more than 14% in early trading, before settling to a gain of 5.42% at HK$196.40, with a trading volume of HK$21.28 million.The company announced that its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02637":"海西新药","BK1191":"制药"},"translate_title":"美国FDA批准HX9428 2期临床试验，海西药业股价飙升逾14%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02637":1},"content_text":"HAIXI PHARMA (02637) shares jumped more than 14% in early trading, before settling to a gain of 5.42% at HK$196.40, with a trading volume of HK$21.28 million.The company announced that its self-developed innovative drug candidate, HX9428, for the treatment of neovascular age-related macular degeneration (nAMD), has received approval from the US Food and Drug Administration (FDA) to commence a Phase 2 clinical trial in the United States. Simultaneously, Haixi Pharma has initiated a second Phase 2 trial in China, using a positive control (Aflibercept), planning to enroll 60 patients.Public information indicates that HX9428 is an oral innovative drug candidate designed to overcome the current reliance on intravitreal injections for nAMD treatment, offering a more convenient dosing regimen to improve long-term patient compliance. Prior studies have completed Phase 1 and Phase 2 dose expansion stages.The company stated that the US Phase 2 approval and the initiation of the controlled study in China represent significant progress in global clinical development. HX9428 has not yet been approved for marketing, and its safety and efficacy require further validation.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1158428386","isCrawlerRequest":true}